RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 78-88
  • New Haven's Marinus Pharmaceuticals Goes Public

    Marinus Pharmaceuticals, an eight-person company working on a drug that may be effective against epileptic seizures, went public Thursday with a stock price of $8 a share. The shares traded as high as $8.16 on Thursday on the NASDAQ exchange, and...
  • Pfizer Slightly Beats Expectations, Leaves Investors Guessing About AstraZeneca

    Pfizer Inc on Tuesday left investors guessing whether it would renew its pursuit of its British rival, AstraZeneca, but said it was considering other deals. The largest U.S. drug maker reported higher-than-expected second-quarter revenue, helped by...
  • Allergan to slash workforce by 1,500

    Allergan to slash workforce by 1,500
    Botox maker Allergan Inc. said Monday that it will cut 1,500 employees, most of them in Southern California, in a cost-cutting effort the Irvine company hopes will help it fight off a hostile takeover bid by a Canadian rival. Stung by criticism that it'...
  • AbbVie takes fight for Irish drugmaker to shareholders

    AbbVie Inc. on Wednesday took its fight for control of the Irish drugmaker Shire Plc directly to shareholders, calling for immediate talks for a transaction it views as "highly executable." The North Chicago-based pharmaceutical firm, know for its...
  • U.S. senators seek review of proposed Valeant buyout of Allergan

    Seven U.S. senators have asked the Justice Department and Federal Trade Commission to review the proposed acquisition of Botox maker Allergan Inc. by a Canadian company, saying the deal could increase consumer pricing and curtail the development of new...
  • Inhaled insulin drug Afrezza, from L.A.'s MannKind, is approved

    Inhaled insulin drug Afrezza, from L.A.'s MannKind, is approved
    Los Angeles billionaire inventor Alfred Mann's almost decade-long quest to develop an inhalable form of insulin for diabetics won approval Friday from U.S. regulators. His Valencia company, MannKind Corp., got the OK to sell the drug called Afrezza,...
  • Maryland overdose deaths jump

    Maryland overdose deaths jump
    An alarming spike in heroin and other drug overdose deaths in Maryland has prompted what the state's health secretary calls an "all hands on deck" effort to investigate and treat addiction. The number of drug- and alcohol-related deaths in Maryland...
  • U.S. regulator approves Afrezza inhalable insulin

    U.S. regulator approves Afrezza inhalable insulin
    After more than a decade of work and nearly $1 billion of his personal fortune, Los Angeles inventor Alfred Mann's quest to develop an inhalable form of insulin for people with diabetes won approval Friday from U.S. regulators. His company, MannKind...
  • MannKind shares rise 10% after insulin drug Afrezza OKd by FDA

    MannKind Corp., the Valencia company that last week won approval to market an inhalable form of insulin to people with diabetes, saw its shares climb 10% on Monday. The Food and Drug Administration announced Friday that it had approved MannKind's drug,...
  • AbbVie forced to retract claims of Shire investor support

    AbbVie forced to retract claims of Shire investor support
    AbbVie Inc. CEO Richard Gonzalez has landed in a bit of hot water for statements he made to certain newswires and U.K. press on Tuesday regarding shareholder support for his company's takeover bid for Shire Plc. The North Chicago-based pharmaceutical...
  • Shire confirms in talks with AbbVie on takeover bid

    Shire confirms in talks with AbbVie on takeover bid
    Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie's takeover bid for the Dublin-based maker of drugs for rare diseases. Shire, in a release, said it would provide a further update "when appropriate." It...